Memorial Sloan Kettering Cancer Center

Virtual Clinical Trials: Monitoring and Auditing During the Pandemic, A Real World Case Study

16 December 2020

Clinical Research Administration Clinical Research Informatics and Technology (CRIT) Clinical Research Quality Assurance (CRQA)

Speakers



Karima Yataghene, MD Clinical Research Quality Assurance Director

Karima is the director of Clinical Research Quality Assurance in the Clinical Research Compliance Unit Division of the Clinical Research Administration. Karima directs and actively manages the development and daily operations of MSK's centralized clinical research quality assurance program. Karima plans for and oversees all internal and external audits across clinical research departments and manufacturing facilities to ensure compliance with all applicable regulations. Ensures top quality research is being performed by tracking key metrics, evaluating risks, creating trend reports and implementing policies and procedures for improvement of the entire MSK clinical research portfolio of clinical trials including industrial, cooperative group, investigator initiated and externally peer reviewed trials.

Karima has more than 20 years of experience in oncology research.



Michael Buckley, MS, MBA Clinical Research Informatics and Technology Enterprise Clinical Research Innovation Manager Co-Chair, Society for Clinical Data Management eSource Implementation Consortium

Michael is the Manager of Enterprise Innovation in the Clinical Research Informatics and Technology Division of the Clinical Research Administration. Michael's focus is on technologically innovative projects to improve the efficiency of clinical trials conduct, refine processes to simplify clinical trials data acquisition, and reduce the time and effort required for the completion of all stages of clinical trials work ranging from aligning and consenting patients through data analysis.





Virtual Monitoring and Auditing


- 1. Background
- 2. Monitoring and Auditing Tracking System (MATS)
- 3. Workflows for Operationalization
- 4. eRegulatory

Closing – Lessons Learned and Best Practices



@MSK 100% eSource Adoption Is Our Goal

MSK applies a suite of technology tools to all clinical trials



eSignature •

Real-time monitoring

feedback (MATS)

Cancer Center.

•

Virtual Monitoring @ MSK: How We Started in 2011 Charge from Leadership for Remote EMR Access

Address onsite monitor/auditor growth

Space

Cost

- Make room for onsite staff growth
- Create solution with low/no cost impact
- Utilize/push existing systems

Improve staff/monitor/auditor satisfaction

Benefits • Increase efficiencies and reduce costs


• Risk mitigate with sponsors/CROs

Partner

MSK Privacy, Legal, Inf. Security




Virtual Monitoring: Three Applications





Virtual Monitoring @ MSK: Initial Pilot to Scale



Monitoring and Auditing Tracking System (MATS)

What is MATS?

MATS is:

- Is a system to schedule industrial monitor/auditor visits,
- request monitor/auditor access to MSK systems during their visits,
- Is an automated online feedback system that is used to collect feedback from industrial monitors/auditors,
- share feedback with MSK study teams and MSK Clinical Research leadership in real-time, and store relevant industrial monitor/auditor visit data.

Feedback Form

At the conclusion of the monitoring/audit visit, the system will send an email to the industrial monitor/auditor containing a link to the feedback form. The intent of the feedback form is to capture real-time feedback after each monitoring visit.

Monitoring and Auditing Tracking System (MATS) MSK Staff Monitor Visit View

| Select Visits: May 21, 2020 | | | | | | October 13, 2 |
|--------------------------------|-----------------|--------------------|-----------|-----------|-----------|---------------|
| Complete | Incomplete | Future Visit | | | | U |
| Overal <u>l Number</u> | of Monitoring \ | /isits by Monitor | | | | |
| | | | | | | 68 Visits |
| | | | | | | 68 Visits |
| | | | | | | 68 Visits |
| | 8 Visits | | 31 Visits | | 19 Visits | |
| | 8 Visits | 19 Visit | \$ | | 30 Visits | |
| | 8 Visits | 19 Visit | 3 | 23 Visit | S | |
| | 8 Visits | 12 Visits | | 24 Visits | | |
| • | 8 Visits | 19 Visit | \$ | 15 Visits | | |
| | 8 Visits | 12 Visits | | 22 Visits | | |
| Protocol Sponsor | IRB# | Monitoring Company | | | | |
| | | | | | | |
| | | | 1 Visits | | | |
| | | | 1 Visits | | | |
| | | | | | | |
| | | | 1 Visits | | | |
| | | | 1 Visits | | | |
| | | | 1 Visits | | | |
| | | | 1 Visits | | | |
| | | | | | | |
| | | | 1 Visits | | | |



Monitoring and Auditing Tracking System (MATS) Monitor View of Feedback Form



Memorial Sloan Kettering Cancer Center

MSK Monitoring Visit Feedback Form

Please complete the MSK Monitoring Visit Feedback Form at the end of your visit. The purpose of this form is to provide you with an immediate means of communication for <u>significant issues/trends</u> identified, if present, directly to the study team and MSK Clinical Research Leadership. We acknowledge that the findings in the feedback form are <u>preliminary</u> and may be adjusted at a later point in time. **As such, this form is not meant to replace or be a duplicate of the Monitoring Visit Follow-Up Letter.** Significant issues not resolved in a timely manner will require a formal response from the study team to MSK Leadership.

MSK Protocol #: 16-392 Sponsor: Syneos Health Date of Visit: 10/01/2020

- 1. Was the study team available via phone or email during the visit to answer questions?
 - \bigcirc Yes
 - \bigcirc No

From: <u>rtmmonitor@mskcc.org</u> <<u>rtmmonitor@mskcc.org</u>> Subject: [EXTERNAL] Reminder: MSK Online Monitoring Visit Feedback Form

Thank you for your recent monitoring visit at Memorial Sloan Kettering Cancer Center. Please complete the MSK Online Monitoring Visit Feedback Form for your visit on **o6/24/2020** for protocol **XX-YYY**. Your feedback will ensure early transparency and real-time escalation of significant findings associated with the monitoring visit. We acknowledge that the findings in the Monitoring Visit Feedback Form are preliminary and do not in any way replace or supersede the Monitoring Visit Followup Letter. Please do not include any PHI in this form. The form should only take a couple of minutes to complete. The preferred web browsers for full functionality of the form are Google Chrome, Firefox or Safari. To start, please **click HERE**.

Your feedback is greatly appreciated.

Sincerely,

Clinical Research Monitoring Program Clinical Research Administration Memorial Sloan Kettering Cancer Center 633 3rd Avenue, 15th Floor, New York, NY 10017 646-227-6028





Who monitors the MATS data?

The data is monitored by the Clinical Research Quality Assurance (CRQA) Unit. Real time review of the Monitoring Visit Feedback forms allow the CRQA to identify and communicate any significant issues/trend identified directly to the study team and MSK CR Leadership quickly.



CRQA Rating Criteria

MATS RATING CRITERIA FOR MONITORING VISITS

Acceptable

No deficiencies/issues identified by monitor

<u>Note</u>: The following deficiencies are NOT considered subject to rating

- Unavailability of study team
- Systems access issue
- Last contact with PI in person or via phone, despite time period even if > 6 months
- Missing documentation due to access issue with EMR
- Monitoring facility not meeting needs

Acceptable Needs Follow Up

Includes one or more of the following criteria:

- Duration of unresolved queries is > 30 days
- Duration of missing data/data not up to date is > 30 days
- Frequent data inaccuracies
- Regulatory binder not up to date
- CRFs/data not available for review
- Missed or out-of-window tests/measures
- Inadequate source documentation of Adverse Events or SAEs
- Inadequate or missing source documentation of protocol treatment (infusion notes, pill diaries, etc.)
- Inadequate or missing source documentation of protocol assessments/ evaluations (response assessments, etc.)
- Specimen sample collection and/or processing not done or done incorrectly
- Drug accountability records and/or temperature logs not available or provided for review

Unacceptable

Includes one or more of the following criteria:

- Duration of unresolved queries is > 90 days
- Duration of missing data/data not up to date is > 90 days
- Consent process executed incorrectly
- Ineligible patient or guestionable eligibility
- Patients dosed incorrectly
- Noncompliance of drug accountability or storage procedures
- Failure to report SAEs to IRB/PB and/or sponsor
- Delayed reporting of SAEs, any timeframe of delay, to IRB/PB and/or sponsor
- Delayed reporting of Outside Safety Reports (IND safety reports) to IRB/PB
- Failure to report protocol deviations to IRB/PB and/or sponsor
- Delayed reporting of protocol deviations to IRB/PB and/or sponsor either > 10 business days or > protocol/sponsor reporting timelines
- Noncompliance with IVRS/IRT procedures and/or randomization procedures and/or randomization procedures


Acceptable letter

Acceptable Needs Follow Up letter

1st & 2nd occurrences: Unacceptable with No Response Required to CRQA letter 3rd consecutive occurrence: Unacceptable with Response Required to CRQA letter




Memorial Sloan Kettering Cancer Center




2019

Memorial Sloan Kettering Cancer Center₁₈



Virtual Monitoring: Access to MSK's EMR Implementation

Study Team Set Up Workflow




Memorial Sloan Kettering Cancer Center.

Timeline: 5 business days


Virtual Monitoring Implementation @ MSK

Monitor/Auditor Non-Employee ID Registration



Timeline: 1 day





Timeline: 10 business days

Memorial Sloan Kettering Cancer Center

Virtual Monitoring Implementation @ MSK CTA Language and Annual Maintenance








Memorial Sloan Kettering Cancer Center...

Case Study: Virtual Monitoring Metrics and Growth

| Total Active Remote Monitors | COVID-19 Additions (included in 922 total) |
|---------------------------------|--|
| 922 | 388 |



COVID-19 increase: 76 %

Memorial Sloan Kettering Cancer Center..

COVID-19 Increase: 65%

Case Study: Virtual Monitoring COVID-19 Learnings

| Year | MSK Users Requesting Visits | Total Monitor/Auditor Visits |
|------------|-----------------------------------|---------------------------------|
| 2019 | 220 | 2,833 |
| 2020 (YTD) | 607 | 4,501 |
| % Increase | 176% | 59% |

Highlights

- Ability to scale quickly during the COVID-19 pandemic
- Acted as a subject matter expert for virtual EHR access
- Shared best practices with domestic and international sites
- Conducted NCI and Cooperative Group Virtual Audits



eRegulatory

Monitors/Auditors see a limited screen based on the MATS DATA

| Memorial Sloan Kettering Cancer Center | Protocol Information Management System | | | | |
|--|--|----------------------------------|---|------------------|--|
| Monitors/Auditors | | | | | |
| MSK Reg Binder Access MSK Document Types | MCPG Reg Binder Access MCPG | Document Types Monitors/Auditors | | | |
| Monitors/Auditors Group Protocol Access | | | | | |
| Internal Monitors/Auditors External Monitors/Auditors Selected Person: test, test monitor | IRB Number | Date From 04/17/2019 09/13/2019 | Date To 04/19/2019 1 09/13/2019 1 | Delete Delete | |



eRegulatory

Monitor view of eReg Binder. Read Only With Restricted Access

| Memorial Sloan Kettering Cancer Center | | Protocol Information Management System |
|--|--------|--|
| | | Regulatory Binder |
| Main Reg Binder | | |
| IRB Number A3 IRB-A | | Regulatory Binder Type MSK V Logged |
| Document Category/Sub Category | Search | Original Protocol |
| Original Protocol | | Meeting Date 01/08/2019 C-N/S |
| Other Original Protocol Documents | Docun | |
| Amendments | Docum | Document Name |
| Other Amendment Protocol Documents | 0 | Sponsor ICF Template |
| IRB Correspondence | | Misc Mesothelioma cohort biostats |
| Continuing Reviews | | |
| Investigator Brochure | 0 | Face Sheet |
| Retrospective Deviations | | Protocol |
| Prospective Protocol Deviations | 0 | Informed Consent |
| Other IRB Correspondence | 0 | Lab Manual |
| Safety Information | 0 | Patient Emergency Card |
| SAEs Submitted to HRPP | 0 | Pill Diary |
| SAEs Not submitted to HRPP | | |
| Outside Safety Correspondence Not Submitted to HRPP | | |
| Outside Safety Correspondence Submitted to HRPP | Review | w Letters |
| Sponsor SAE Reports | | Document Name |
| Sponsor Correspondence | 0 | Conditions Not Satisfied Letter |
| Sponsor Correspondence | 0 | Initial Approval Letter |
| FDA Correspondence | | |
| monitoring | | |
| External Monitoring | ~ | |


Memorial Sloan Kettering Cancer Center₁₅

Virtual Monitoring @ MSK: 2011 to Present Return On Investment

| Productivity | Reclaimed 3h per visit for monitor and research associates, from 4h average → 1h fixed apt. | | |
|----------------|--|--|--|
| Data Readiness | Increased the turnaround time of query resolution from 2-4 weeks to 5 days Increase data verification visits; not space dependent | | |
| Satisfaction | Monitors provided protocol level access for trending AEs, Rxns, Dosing Site personnel | | |
| Cost Savings | 2012 sponsor productivity analysis showed a per monitor per protocol cost savings of \$17.5K/year | | |
| | | | |



Closing-Lessons Learned





Thank You

Clinical Research Administration

- Dr. Eric Cottington
- Dr. Paul Sabbatini
- Dr. Stephanie Terzulli
- Joseph Lengfellner
- Collette Houston
- Nicholas Cimaglia

Clinical Research Quality Assurance

- Francine Puma
- Adrian Granobles
- Kamala Mantha-thaler

Research Technology Management

Lee Stetson

Information Security

Michael Czumak

Clinical Research Informatics and Technology

- Kristopher Kaufman
- Brian Seko
- Matt Koch
- Marcia Latif
- Dawn Caron
- Joshua Levine
- Hector Pacheco

Health Informatics

- Mary Mitchelle
- Jay Washington
- Cynthia Hutchinson

Privacy

- Kristen Ahearn
- Jessica Palla
- Joanna Halperin

